Connect with us

American Cannabis News

Cresco Labs Reports 11% Q2 Revenue Decline – New Cannabis Ventures

Published

on

Cresco Labs Reports 11% Q2 Revenue Decline – New Cannabis Ventures

CRESCO LABS SOLID Q2 PAINTING AND DEPARTMENT Refinancing The basis for the creation of long-term value

Chicago- (Business Wire) – CRESCO LABS INC. (CL) (OTCQX: CRLBF) (FSE: USD, unless otherwise stated and available on the company’s investors’ website, here.

The second quarter 2025 important events

  • The income of the second quarter of $ 164 million. The second quarter, which operates cash flow, $ 9 million.
  • Gross profit: $ 83 million. Adjusted gross profit – $ 83 million; and adjusted gross margin in the amount of 50.6% of income.
  • SG & A $ 51 million or 31.4% of income.
  • The net loss of $ 14 million includes an unresolved charging of $ 9 million in California’s assets.
  • The second quarter adjusted Ebitda¹ to $ 41 million and adjusted Ebitda margin, 25.0%.
  • Maintained the position of shares # 1 in many billion dollars markets.

Management Comment:

In Q2, we showed strongly in accordance with the guidance, preserved the share of our market in a high competitive environment and continued to make cash with our balance and maintains our balance sheet. Near time priorities and long-term growth opportunities. “

“The hemp industry enters a new phase, which is defined by consolidation and intelligence. choice partner as a consolidation of industry. “

Balance, liquidity and other financial information

  • As of June 30, 2025, current assets amounted to $ 315 million, including cash and cash equivalents, $ 147 million. The company had a senior secured credit loan debt, discount and release costs, $ 354 million and mortgage loans, discount net and release costs.
  • The shares of voting on a fully converted basis were 483.444.948, as of June 30, 2025.

“Non-GAAP FINANCIAL” “NON GAAP FINANCIAL”, the company’s non-GAP financial measures for the use of financial events.

²Achding to Hoodie Analytics.

Conference call and web wash

The company will host a conference call and web web, on Thursday, August 7, 2025, Eastern time. 30 o’clock at 8 o’clock. On 30. The conference call can access WEBCAST or 1-433-470-1428 or 1-404-975-4839 (Local) provides 158138 access code.

CRESCO LABS INC.

CRESCO LABS mission is to normalize the cannabis industry and professionalize the construction of national brands and the construction of a customer-based retail experience, while a business economy for existing legislative and regulatory initiatives. As a leader of cultivation, production and brand distribution, the company uses its scale and agility to grow its brands portfolio, which includes CRESCO, High Supply, Floracal, Good news, Mindy’s and Remedi, Mindy’s and Remedi. The company also operates very effective dispenses, which are located under the Sunnyside brand, which focus on the construction of the patient’s and consumer confidence during continuous education and convenience. Efforts to the Community Area and Seed Initiative throughout the Policy, CRESCO Labs presents the responsibility of supporting communities through valid involvement, economic opportunities, investments, labor, and legislative initiatives, which have been developed as possible. Learn more about Cresco Labs travel by visiting www.crescolabs.com or Following the company on Facebook, X or LinkedIn.

Original press release

Published by NCV NewsWire

NCV NewsWire:

NCV NewsWire aims to treat high-quality content and information about cannabis companies by New Cannabis Ventures to help our readers make noise and remain the most important cannabical business news. NCV Newswire is hand treated by hand and is not automated. Have secret news tip. Contact:A number

Get our Sunday newsletter





AdvisorShares Pure US Cannabis ETF

Cannabis Stocks Are Sinking – New Cannabis Ventures

Published

on

By

Cannabis Stocks Are Sinking – New Cannabis Ventures

You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

The Global Hemp Stock Index closed 2/11 at 5.69, down 3.4% in February and 13.7% year-to-date in 2026. Since April 30, 2024, it has fallen by 51.4%. The index peaked at 92.48 five years ago and has since declined 93.9%.

Many are keeping an eye on the AdvisorShares Pure US Cannabis ETF (NYSE Arca: MSOS ) and it is down 16.1% so far in 2026, and since 4/30/24 the decline has been a massive 64.8% to its current $3.96. That’s only slightly higher than $3.81, where it ended 2024, and well above the all-time low of $2.02 set in April of last year. The ETF currently has about 2/3 of its portfolio in just three MSOs. Including four other positions above 5%, the top 7 represent 93.6% of MSOS.

Cannabis stocks are clearly under pressure. The 27 stocks in the Global Hemp Stock Index were mostly lower, although two of the stocks rose more than 15%, Scotts Miracle-Gro and Turning Point Brands. Neither of these two companies exclusively serve the hemp industry. 7 stocks fell by more than 20%, three of which fell by more than 44%.

A few companies reported quarters that ended 12/31, but most of the companies in the index had their year ending and will report them later this month. I’ll share a preview before then. I don’t think financial statements are what it will take to make things right for hemp stocks. Instead, it requires a rearrangement that will result in termination 280E taxwhich I discuss in this weekly newsletter from late 2022. The good news is that it is still potentially alive. I continue to suggest that it should not be assumed that this will happen. It should happen, and it would be good if it happened. Good luck to all consumers, medical patients, industry workers and investors.

Sincerely,

Alan:


New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.

Exclusives

Cannabis sales fell in January

Hemp stocks are off to a bad start in 2026

Illinois provides another cannabis update

Capital increase

Canadian LP Decibel extends debt

Trulieve owes another $60 million

Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading

American Cannabis Coverage by State

Cannabis Sales Slipped in January – New Cannabis Ventures

Published

on

By

Cannabis Sales Were Soft Again – New Cannabis Ventures

On February 3, 2026 at 8:42 PM

New Cannabis Ventures offers readers this easy-to-read exclusive summary of BDSA’s 15-state monthly cannabis sales data.

In January, cannabis sales decreased sequentially by 3.1%. In this review, we break down the results by state, starting with the western markets and then ending with the eastern markets. Overall, the BDSA estimates sales in 15 markets totaled $2.07 billion in January, up 4.6 percent from a year earlier. BDSA updated its Illinois numbers after the state recently changed the way it counts sales.

Western markets

BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In December, annual growth was negative in 4 states. Growth in each of these states fell in succession.

Eastern markets

BDSA provides coverage for Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri, New Jersey, New York, Ohio and Pennsylvania. Annual growth in December ranged from -3.1% in Missouri to +37.6% in New York. Ohio began using adults in August, spurring growth. Note that Florida and Pennsylvania are medical markets only. On a daily basis, sequential gains declined in eight markets. Annual growth was negative in both markets and sharp in both states. We warned of a potential slowdown in Florida despite strong dispensary and unit volume growth due to competitive pressure.

For readers interested in a deeper look hemp markets in these fifteen states and more, including segmentation by additional product categories, brand and product details, longer history and segmentation by product attributes, learn how BDSA Solutions can give you access to actionable data and analytics.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading

4Front

Illinois Provides Another Cannabis Update – New Cannabis Ventures

Published

on

By

Illinois Cannabis Data Change Suggests Much Lower Sales – New Cannabis Ventures

Illinois released sales figures for two months on Friday. The last time it released the data in November, the state did a major review of historical sales after a long delay, and it was updated to October. The previous report was for Cannabis for adults in May. The November document explained that the lack of data was due to the Metrc transition. “Sales tracking features in Metrc help retailers more accurately and reliably report actual sales, including all discounts and promotions at checkout. A careful review of past data shows that some initial discount prices were collected in previous months.” Here is the updated data until the end of 2025.

Statewide adult cannabis sales rose 5.6% sequentially to $116.6 million in December, up 2.2% on the day. Year-on-year growth was -23.9%, a slight improvement from November’s -26.1% growth. Here is a chart of adult sales over time:

After growing 106% in 2021, 13% in 2022 and 5% in 2023, annual sales for adults are set to grow 5.4% to $1.72 billion in 2024. In 2025, they decreased by 12.5% ​​to $1.51 billion, which was lower than the total in 2022.

There hasn’t been an update from the state on medical cannabis in a while. The state exempts the sale separately from its medical plan, and April issue showed that sales fell 1.6% sequentially to $19.7 million, down 13.2% year over year.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media